Home > Healthcare > Pharmaceuticals > Finished Drug Form > myeloproliferative disorders drugs treatment market
Get a free sample of Myeloproliferative Disorders Drugs/Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Myeloproliferative Disorders Drugs/Treatment Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Several key players are intensely involved in R&D activities aimed at introducing cutting-edge treatments for myeloproliferative disorders. These companies prioritize the development of targeted therapies such as JAK inhibitors in their pursuit of capturing market share. Additionally, they actively pursue collaborative research efforts and seek market authorization for effective treatment options to establish and uphold their leading position in the fiercely competitive market landscape.
Prominent players operating in the myeloproliferative disorders drugs/treatment industry are as mentioned below:
The JAK inhibitors segment is anticipated to witness 3.1% CAGR over 2024-2032, owing to the growing research on introducing effective treatments for the rare hematological disorder.
North America market accounted for 41.9% revenue share in 2023, owing to the presence of advanced healthcare infrastructure and facilities in the region.
The market size of myeloproliferative disorders drugs/treatment reached USD 9.3 billion in revenue in 2023 and is set to witness 3.2% CAGR through 2032, driven by the increasing availability of novel drugs worldwide.
Some top myeloproliferative disorders drugs/treatment firms are AbbVie Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc (GSK), GL Pharma Gmb, Incyte Corporation, Janssen Biotech, Inc. (Johnson & Johnson), MorphoSys AG, Mylan N.V. (Viatris), Novartis Pharmaceuticals Corporation (Novartis AG), Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.